Patents by Inventor Charles M. Cohen
Charles M. Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5972884Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: GrantFiled: June 5, 1995Date of Patent: October 26, 1999Assignee: Creative BioMolecules, Inc.Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang
-
Patent number: 5854071Abstract: Disclosed are (1) nucleic acid and amino acid sequences for a novel morphogenic protein; (2) methods for producing and expressing the protein in a biologically active form; and (3) methods for utilizing the protein to induce tissue morphogenesis in a mammal, including methods for increasing a progenitor cell population in a mammal, methods for stimulating progenitor cells to differentiate and maintain their differentiated phenotype in vivo or in vitro, methods for inducing tissue-specific growth in vivo and methods for the replacement of diseased or damaged tissue in vivo.Type: GrantFiled: July 28, 1997Date of Patent: December 29, 1998Assignee: Creative BioMolecules, Inc.Inventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang, Charles M. Cohen
-
Patent number: 5849686Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining liver function in a mammal, including methods, compositions and devices for regenerating lost or damaged hepatic tisse, enhancing viability and integration of hepatic tissue and organ transplants, and correcting liver function deficiencies. The methods, compositions and devices on this invention all provide a therapeutically effective morphogen concentration to the hepatic cells to be treated.Type: GrantFiled: May 22, 1995Date of Patent: December 15, 1998Assignee: Creative BioMolecules, Inc.Inventors: Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang, Charles M. Cohen
-
Patent number: 5741641Abstract: Disclosed is a method of screening candidate compounds for the ability to modulate the level of morphogenic protein in mammalian system. The method includes determining a parameter indicative of the level of production of a morphogenic in a cell culture known to produce the morphogen, incubating a candidate compound with the culture for a time sufficient to allow the compound to affect the production of the morphogenic protein, and then assaying the culture again to detect a change in the level of morphogenic protein production.Type: GrantFiled: May 26, 1995Date of Patent: April 21, 1998Assignee: Creative BioMolecules, Inc.Inventors: John E. Smart, Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang, Charles M. Cohen
-
Patent number: 5739107Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.Type: GrantFiled: June 5, 1995Date of Patent: April 14, 1998Assignee: Creative BioMolecules, Inc.Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang, Engin Ozkaynak, John E. Smart
-
Patent number: 5733878Abstract: Disclosed are methods and compositions for inducing periodontal tissue morphogenesis in a mammal which include a therapeutically effective concentration of a morphogen. The methods and compositions are useful for integrating an implanted tooth in a tooth socket and for inhibiting tissue loss associated with periodontal disease or injury.Type: GrantFiled: May 6, 1996Date of Patent: March 31, 1998Assignee: Creative BioMolecules, Inc.Inventors: Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Charles M. Cohen, Roy H. L. Pang
-
Patent number: 5707810Abstract: In one aspect, the present invention provides a method of diagnosing renal tissue damage or disease by measuring endogenous expression of OP-1 by renal tissue of a mammal (e.g., a human) in which a depression of endogenous expression relative to undamaged or undiseased mammalian renal tissue indicates a diagnosis that the mammal is afflicted with renal tissue damage or disease. Also disclosed are methods of diagnosing renal tissue damage or disease in a mammal. The methods involve detecting and/or measuring the expression of the OP-1 (BMP-7) gene or protein in the mammal. Depression of OP-1 expression may be used to diagnose renal tissue damage or disease.Type: GrantFiled: May 6, 1996Date of Patent: January 13, 1998Assignee: Creative BioMolecules, Inc.Inventors: John E. Smart, Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang, Charles M. Cohen
-
Patent number: 5700677Abstract: Protein analogues of tissue plasminogen activator (tPA) are described. The analogues exhibit the proteolytic function of natural tPA and optionally fibrin binding activity, but are molecules, generally of lower molecular weight than natural tPA, designed for efficient expression in prokaryotic host cell systems. The analogues can comprise a catalytic fragment of tPA or a catalytic fragment of tPA linked to a polypeptide which stabilizes the catalytic fragment, provides for efficient expression of the fragment or confers a fibrin binding capability. Fibrin binding polypeptides can be a polypeptide fragments derived from tPA which embody the fibrin binding domain(s) of natural tPA or they can be an exogenous (non-tPA) polypeptides of eukaryotic or prokaryotic origin which exhibit fibrin binding affinity such as the antigen binding fragment of an antifibrin immunoglobulin or the B domain of protein A. Genetic constructs for expression of the analogues are also provided.Type: GrantFiled: November 27, 1991Date of Patent: December 23, 1997Assignees: Creative BioMolecules, Inc., A. Menarini S.A.S.Inventors: Roberto Crea, Roy Hoi Loi Pang, Hermann Oppermann, Peter C. Keck, Gabriel Alvarado-Urbina, Gay-May Wu, Charles M. Cohen
-
Patent number: 5674844Abstract: The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.Type: GrantFiled: March 20, 1995Date of Patent: October 7, 1997Assignee: Creative BioMolecules, Inc.Inventors: Thangavel Kuberasampath, Charles M. Cohen, Hermann Oppermann, Engin Ozkaynak, David C. Rueger, Roy H. L. Pang
-
Patent number: 5656593Abstract: Disclosed are methods and compositions for inducing periodontal tissue morphogenesis in a mammal which include a therapeutically effective concentration of a morphogen. The methods and compositions are useful for integrating an implanted tooth in a tooth socket and for inhibiting tissue loss associated with periodontal disease or injury.Type: GrantFiled: November 15, 1993Date of Patent: August 12, 1997Assignee: Creative BioMolecules, Inc.Inventors: Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Charles M. Cohen, Roy H. L. Pang
-
Patent number: 5652337Abstract: Disclosed are (1) nucleic acid and amino acid sequences for a novel morphogenic protein; (2) methods for producing and expressing the protein in a biologically active form; and (3) methods for utilizing the protein to induce tissue morphogenesis in a mammal, including methods for increasing a progenitor cell population in a mammal, methods for stimulating progenitor cells to differentiate and maintain their differentiated phenotype in vivo or in vitro, methods for inducing tissue-specific growth in vivo and methods for the replacement of diseased or damaged tissue in vivo.Type: GrantFiled: June 7, 1995Date of Patent: July 29, 1997Assignee: Creative BioMolecules, Inc.Inventors: Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H. L. Pang, Charles M. Cohen
-
Patent number: 5650276Abstract: Disclosed is a method of screening candidate compounds for the ability to modulate the level of morphogenic protein in mammalian system. The method includes determining a parameter indicative of the level of production of a morphogenic in a cell culture known to produce the morphogen, incubating a candidate compound with the culture for a time sufficient to allow the compound to affect the production of the morphogenic protein, and then assaying the culture again to detect a change in the level of morphogenic protein production.Type: GrantFiled: July 20, 1994Date of Patent: July 22, 1997Assignee: Creative BioMolecules, Inc.Inventors: John E. Smart, Hermann Oppermann, Engin Ozkaynak, Thangavel Kuberasampath, David C. Rueger, Roy H.L. Pang, Charles M. Cohen
-
Patent number: 5416007Abstract: Disclosed are methods for increasing the yield of intact target proteins by cleaving fused polypeptides made by recombinant DNA techniques. The fused polypeptides are designed at the DNA level to have a preselected primary cleavage site in a pendant polypeptide fused to a protein of interest. Structural features of the fused polypeptide and cleavage reaction environment are controlled to favor cleavage by a preselected cleavage agent at the primary cleavage site over a second cleavage agent-sensitive amino acid sequence in the target protein. The cleavage reaction is terminated before completion when the ratio of intact target protein to truncated, cleaved target protein is optimized, and the remaining reaction mixture comprising uncleaved fused polypeptide is resubjected to the cleavage agent. The presence of charged organic molecules in the cleavage reaction mixture favors cleavage at the primary cleavage site. The endopeptidase used for cleavage may be immobilized on an insoluble support matrix.Type: GrantFiled: July 12, 1994Date of Patent: May 16, 1995Assignee: Creative BioMolecules, Inc.Inventors: Marc F. Charette, Roberto Crea, Charles M. Cohen
-
Patent number: 5374431Abstract: This invention pertains to a synthetic adhesive composition for use in aqueous environments. The composition comprises polypeptide chains having an .alpha.-helical structure in aqueous environments and capable of cohesive and adhesive interactions. The polypeptide chains comprise polar and apolar amino acids, the apolar and polar amino acids being arranged to define apolar and polar vertical spiraling stripes on the helix surface. The apolar stripes allow the polypeptide chains to aggregate into superhelical structures and the polar stripes allow interchain crosslinking within and between the superhelical structures.Type: GrantFiled: December 10, 1992Date of Patent: December 20, 1994Assignee: Creative Biomolecules, Inc.Inventors: Roy H. L. Pang, Charles M. Cohen, Peter C. Keck
-
Patent number: 5330902Abstract: Disclosed is a novel polypeptide useful as a leader or trailer peptide moiety in recombinant DNA protein production techniques involving fused protein methodology. The polypeptide comprises an amphiphilic helix designed at the DNA level to have hydrophilic charged amino acid residues on one side of the barrel of the helix and nonpolar amino acid residues on the other side of the barrel of the helix. When DNA encoding the helix is attached to a gene encoding a protein of interest, high level expression is achieved and inclusion bodies are spontaneously formed. The inclusion bodies may be collected and purified easily by altering the ionic strength and/or pH of media used to dissolve the inclusion bodies. After purification, the fused protein is cleaved to separate the amphiphilic helix from the product.Type: GrantFiled: January 15, 1993Date of Patent: July 19, 1994Assignee: Creative BioMolecules, Inc.Inventors: Peter C. Keck, Charles M. Cohen, James S. Huston, Richard J. Ridge
-
Patent number: 5302526Abstract: Disclosed is a novel polypeptide useful as a leader or trailer peptide moiety in recombinant DNA protein production techniques involving fused protein methodology. The polypeptide comprises an amphiphilic helix designed at the DNA level to have hydrophilic charged amino acid residues on one side of the barrel of the helix and nonpolar amino acid residues on the other side of the barrel of the helix. When DNA encoding the helix is attached to a gene encoding a protein of interest, high level expression is achieved and inclusion bodies are spontaneously formed. The inclusion bodies may be collected and purified easily by altering the ionic strength and/or pH of media used to dissolve the inclusion bodies. After purification, the fused protein is cleaved to separate the amphiphilic helix from the product.Type: GrantFiled: January 15, 1993Date of Patent: April 12, 1994Assignee: Creative BioMolecules, Inc.Inventors: Peter C. Keck, Charles M. Cohen, James S. Huston, Richard J. Ridge
-
Patent number: 5215896Abstract: Disclosed is a novel polypeptide useful as a leader or trailer peptide moiety in recombinant DNA protein production techniques involving fused protein methodology The polypeptide comprises an amphiphilic helix designed at the DNA level to have hydrophilic charged amino acid residues on one side of the barrel of the helix and nonpolar amino acid residues on the other side of the barrel of the helix. When DNA encoding the helix is attached to a gene encoding a protein of interest, high level expression is achieved and inclusion bodies are spontaneously formed. The inclusion bodies may be collected and purified easily by altering the ionic strength and/or pH of media used to dissolve the inclusion bodies. After purification, the fused protein is cleaved to separate the amphiphilic helix from the product.Type: GrantFiled: March 25, 1992Date of Patent: June 1, 1993Assignee: Creative BioMolecules, Inc.Inventors: Peter C. Keck, Charles M. Cohen, James S. Huston, Richard J. Ridge
-
Patent number: 5197973Abstract: This invention pertains to a synthetic adhesive composition for use in aqueous environments. The composition comprises polypeptide chains having an .alpha.-helical structure in aqueous environments and capable of cohesive and adhesive interactions. The polypeptide chains comprise polar and apolar amino acids, the apolar and polar amino acids being arranged to define apolar and polar vertical spiraling stripes on the helix surface. The apolar stripes allow the polypeptide chains to aggregate into superhelical structures and the polar stripes allow interchain crosslinking within and between the superhelical structures.Type: GrantFiled: December 14, 1990Date of Patent: March 30, 1993Assignee: Creative BioMolecules, Inc.Inventors: Roy H. L. Pang, Charles M. Cohen, Peter C. Keck
-
Patent number: 5013653Abstract: Disclosed is a method for the isolation and purification of polypeptides expressed in host cells by recombinant DNA techniques. A fused polypeptide is produced containing a desired polypeptide fused to additional amino acids. The additional amino acids define a leader sequence having properties exploitable in purification, a hinge region, and a cleavage site. The hinge region is cysteine-free and has a secondary structure which serves to expose the cleavage site to a selected endopeptidase. The method of the invention involves the production of a fused polypeptide which may be efficiently isolated by exploiting the properties of the leader sequence, and then efficiently cleaved at the cleavage site in an appropriate aqueous environment by virtue of the influence of the hinge on the cleavage agent/cleavage site reaction and other properties of the fused polypeptide.Type: GrantFiled: December 28, 1989Date of Patent: May 7, 1991Assignee: Creative Biomolecules, Inc.Inventors: James S. Huston, Marc F. Charette, Charles M. Cohen, Roberto Crea, Peter C. Keck, Hermann Oppermann, David C. Rueger, Richard J. Ridge
-
Patent number: 5004686Abstract: Disclosed is a process for producing a fusion protein of epidermal growth factor (EGF) attached through a Glu-residue, treatment of the fusion protein with a Staphylococcus aureus protease specific for cleaving peptides at a Glu-linkage thereby producing large amounts of the 53 amino acid EGF sequence.The treatment conditions optimize production of large amounts of the 53 amino acid sequence relative to the 51 amino acid sequence minus the 52 Leu and 53 Arg residues and take full advantage of the selectivity of the protease.Type: GrantFiled: January 4, 1988Date of Patent: April 2, 1991Assignee: Creative Biomolecules, Inc.Inventors: Charles M. Cohen, Roberto Crea